Anemia in Low-risk MDS: Current Treatment and Trials in Progress

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: December 12, 2018
Expiration Date: December 12, 2019

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

A majority of patients with low-risk MDS will develop symptomatic anemia over time. Practitioners are often challenged with the goal to minimize symptoms, improve blood counts, and decrease transfusions. In this activity, Dr. Gore reviews the efficacy and safety data of current and emerging therapies for anemia in low-risk MDS.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including primary care physicians, hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe treatment issues related to chronic anemia in patients with RBC transfusion dependence
  • Assess the current unmet need in treatment availability for patients who are transfusion dependent
  • Outline the efficacy and safety of current and emerging agents that are used to treat anemia and their overall impact in patients currently burdened with chronic anemia related to MDS

Agenda

Anemia in Low-risk MDS: Current Treatment and Trials in Progress – Steven D. Gore, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 12, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Steven D. Gore, MD 
Professor of Internal Medicine, Section of Hematology
Yale University
Director of Hematologic Malignancies
Yale Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut

Dr. Steven Gore has been a leader in drug development in myeloid malignancies, focusing on the optimization of putatively epigenetically targeted agents, and understanding of their mechanism of action. He served on the oncology faculty at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in the Division of Hematologic Malignancies from 1990 through 2013. Since 2013 he has directed Hematologic Malignancies at the Yale Cancer Center and Smilow Cancer Hospital. He serves on the NCI Leukemia Steering Committee and is co-chair of the National Heart, Lung, and Blood Institute (NHLBI) Myelodysplastic Syndromes (MDS) Natural History Study.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-049-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Steven Gore has received honoraria as a consultant from AbbVie Inc., Celgene Corporation, Kyowa Kirin Pharmaceutical Development, Inc., and Tolero Pharmaceuticals. He has received grant support related to research activities from Actinium Pharmaceuticals, Inc. and Celgene.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Onconova Therapeutics, Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.